Who this treatment is actually for

For many people, the first question about ChondroFiller injection is a simple one: does my hip qualify? The honest answer is that it depends on two things — the nature of the cartilage damage and the overall condition of the joint.

ChondroFiller injection is suited to focal, contained cartilage defects: areas where the cartilage has worn through to Grade III or IV (deep partial or full-thickness loss) on the acetabulum or femoral head, typically between 2 and 4.5 cm² in size. These are localised patches of damage, not a joint-wide problem.

Equally important is the state of the surrounding joint. Imaging assessment uses the Tönnis grading system — think of it as a weather forecast for how much background arthritis is already present. Grades 0 and 1 indicate a joint still in good enough shape to support biological repair; published cohort data show consistently good to excellent results in this group. Patients with Tönnis Grade 2 or 3 — meaning moderate to severe osteoarthritis with significant joint-space narrowing — consistently achieve poor results and are not appropriate candidates.

The typical candidate is an active adult with a symptomatic focal lesion, often following femoroacetabular impingement (FAI) or a hip injury, whose joint has not yet crossed into advanced arthritis. ChondroFiller injection is not a treatment for diffuse cartilage loss across the hip; patients in that situation require a separate discussion about joint preservation or replacement.

How the collagen scaffold promotes repair

Unlike steroid or hyaluronic acid injections — which address pain and inflammation rather than the tissue itself — ChondroFiller injection works by placing a physical structure directly inside the cartilage defect. There are no donor cells in the product; the collagen itself is the active element.

The material is a liquid Type I collagen hydrogel that, once positioned within the defect under ultrasound guidance, self-sets in situ within minutes, conforming precisely to the shape of the lesion. Think of it as temporary scaffolding erected inside a gap in a wall: the structure is not the finished repair, but it creates the environment in which repair becomes possible.

Once set, the collagen matrix releases molecular signals that draw the patient's own chondrocytes and progenitor cells into it from the surrounding tissue. Those cells migrate into the scaffold, begin to differentiate, and deposit new repair tissue as the collagen gradually biodegrades and is replaced. An ex vivo model supports this: cellular content within the scaffold increased 2.4-fold by day 14, confirming meaningful host cell migration into the matrix.

This places ChondroFiller injection at the cartilage restoration stage of the treatment pathway — distinct from symptom-management injections such as PRP or corticosteroid on one side, and from two-stage cell-based surgical procedures such as ACI or MACI on the other. It is a CE-marked Class III medical device, not a pharmaceutical or biologic, and its role is structural: to provide the matrix within which the body's own repair process can take hold.

The outpatient injection: what the procedure involves

On the day of treatment, the appointment is straightforward: patients arrive at the clinic, receive a local anaesthetic to the hip area, and the injection is performed using real-time ultrasound to guide needle placement directly into the defect. There is no theatre booking, no general anaesthetic, and no overnight stay.

For hip injections specifically, that imaging guidance is not optional. Landmark-guided hip injections — where the clinician positions the needle by surface anatomy alone — achieve accurate intra-articular placement in only around 72% of cases. Ultrasound guidance brings that figure to near-100%. The reason this matters is anatomy: the femoral artery and vein run approximately 1.9 cm and 1.7 cm medial to the hip capsule respectively, and the femoral nerve sits around 2.3 cm lateral. The lateral circumflex femoral artery also takes a variable course across the front of the hip. Naming these structures is not intended to alarm — it simply explains why image guidance is standard practice and why it makes the procedure reliably safe.

Application volume requires equal care during placement. Evidence from joint studies shows that overfilling a defect promotes fibrous tissue rather than cartilage-like repair tissue, whereas flush application — filling the lesion precisely level with the surrounding surface — gives better outcomes.

Some published research describes an arthroscopic delivery route, used in theatre settings to navigate the constrained anatomy of the acetabulum. Those studies are cited elsewhere in this article as efficacy evidence; they represent a distinct clinical pathway and are not the current outpatient injection service.

What the clinical evidence shows

The strongest published evidence for the hip comes from a prospective cohort of 26 patients with femoroacetabular impingement and acetabular cartilage lesions larger than 2 cm². At 3–5-year follow-up, 17 of the 21 patients available for review had achieved good or excellent results; two required conversion to total hip replacement. That is a meaningful signal of durability, but this is a single-centre series with small numbers — it establishes a credible track record, not a definitive verdict.

The femoral side of the hip is represented by a 2025 case report: a 32-year-old male with a 15 mm × 5 mm lesion on the superoanterior weight-bearing dome of the femoral head achieved complete pain relief and full range of motion restoration after ChondroFiller application, without microfracture. One case cannot establish population-level outcomes, but it does confirm the treatment applies to femoral-head lesions as well as the acetabular side — anatomically significant, given that lesion site can determine which patients are assessed as candidates.

Across knee cohorts, IKDC scores improve by approximately 30 points at one year, and hip functional outcome data follow a comparable pattern. A small randomised controlled trial confirmed statistically significant IKDC improvements at 3, 6, and 12 months with no adverse events reported — cross-joint safety reassurance, though not hip-specific evidence. The overall complaint rate across reported ChondroFiller use sits at approximately 0.06%.

The gaps in the evidence deserve plain statement. Large randomised trials specific to the hip do not yet exist. There are no long-term comparative data beyond five years distinguishing outcomes by lesion site — acetabular versus femoral head. No prospective study has compared the outpatient injection route with arthroscopic delivery for hip applications. These are the conditions under which the existing evidence should be read.

ChondroFiller is available in the UK and across Europe; it does not currently hold FDA approval in the United States.

Recovery, weight-bearing, and the weeks after injection

The question most patients ask before leaving the consultation is some version of: 'When can I walk normally again?' It is worth being direct about what this treatment is and is not — ChondroFiller injection is a repair process, not a pain-blocking agent, and recovery is measured in weeks to months rather than days.

The reason for a protected weight-bearing period after the injection is not arbitrary caution. An in-vitro cyclic-load study found that the collagen scaffold, in its initial state, does not protect the opposing cartilage surface under physiological loads of around 33 N. Put simply, the gel needs time to bond to the defect bed and be reinforced by the incoming repair tissue before the joint can tolerate full loading without risk of displacing or disrupting it. Restriction during this window is mechanically justified by what happens at the tissue level.

As that repair tissue gradually matures, symptomatic improvement tends to build progressively — patients should not expect to feel markedly different in the first few weeks. The precise weight-bearing and activity schedule varies by defect size, location, and individual healing response, and is set by the treating clinician rather than a fixed protocol.

Return to activity is a structured progression guided by symptoms and review appointments, not a single clearance moment. Patients whose underlying joint health was at the margin of the treatment indication — those with higher Tönnis grades at assessment — should be aware that the repair environment is less favourable, which is consistent with the outcome data showing that joint condition at the time of treatment influences how well the scaffold integrates.

Getting assessed for ChondroFiller injection at London Cartilage Clinic

Establishing suitability begins with a structured clinical assessment — not a self-referral checklist. At the London Cartilage Clinic on Harley Street, that assessment typically involves an MRI to characterise defect size, depth, and location, alongside weight-bearing X-rays to determine Tönnis grading and rule out meaningful joint-space narrowing. Clinical review of symptoms, hip mechanics, and functional demands sits alongside the imaging: a defect that appears suitable on MRI may still require a different approach if there is concurrent femoroacetabular impingement, malalignment, or broader degenerative change that ChondroFiller injection alone cannot address.

Professor Paul Y. F. Lee leads hip cartilage assessment at the clinic and will advise whether ChondroFiller injection represents the right pathway — or whether an alternative such as OATS, MACI, or, in end-stage cases, a joint replacement discussion is more appropriate. For patients who cannot easily travel to London, MSK Doctors' sites in Lincolnshire and Grantham offer an alternative access point for this assessment.

To arrange a consultation and imaging review, visit londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
5. [5] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y